MAPT and amyloidosis: The regulation of O-GlcNAc can activate the non-amyloid pathway of APP, downregulate the amyloidosis pathway, reduce the production of Aβ, promote the cleavage of generated Aβ, prevent the subsequent nerve damage caused by the hyperphosphorylation of Tau induced by Aβ, reduce the number of tangles of Tau neurons modified by O-GlcNAc, and inhibit neurodegeneration (Akasaka-Manya and Manya, 2020).